SSTR2-Targeted BiTE and CAR-T Therapy for Neuroendocrine Tumors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapy treatments for neuroendocrine tumors (NETs) have not demonstrated significant activity, particularly in well-differentiated forms, despite the overexpression of somatostatin receptors in these tumors.
Innovation Solution
Development of Bispecific T-Cell Engaging (BiTE) molecules and chimeric antigen receptors (CAR) that crosslink CD3 on immune effector cells with SSTR2 on NETs, enabling targeted immunotherapy through engineered CAR-T cells that secrete BiTE molecules and somatostatin, cytokines, or antibodies upon activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard immunotherapy treatments are used, then the treatment approach is conventional and easy to administer, but they have not demonstrated significant activity in well-differentiated neuroendocrine tumors
Solution Approach 1:
The patent introduces BiTE molecules as intermediary agents that bridge T-cells and SSTR-expressing tumor cells. These bispecific T-cell engaging molecules contain one arm binding to CD3 on T-cells and another arm binding to SSTR2 on tumor cells, facilitating targeted immune engagement that overcomes the limitations of standard immunotherapy while maintaining a manageable treatment complexity through targeted mechanism
Solution Approach 2:
The patent modifies the immunotherapy approach by changing key parameters: using engineered CAR-T cells with enhanced activation properties, incorporating costimulatory domains (CD28, 4-1BB) to improve T-cell persistence and potency, and utilizing BiTE molecules with optimized binding affinities. These parameter changes transform conventional immunotherapy into a more effective targeted therapy for well-differentiated NETs
2Measurement precision
If BiTE molecules and CAR-T cells are engineered to target SSTR2, then specific binding to SSTR-expressing cancers is achieved, but the manufacturing and engineering complexity increases
Solution Approach 1:
The patent segments the immunotherapy system into modular components: separate BiTE molecules with defined binding specificities, CAR-T cells with standardized construction modules (antigen recognition domain, hinge, transmembrane, intracellular signaling domains), and cytokine delivery systems. This segmentation enables independent optimization of each component's binding specificity while facilitating standardized manufacturing protocols for each module
Solution Approach 2:
The patent creates universal CAR-T cell constructs that can target different SSTR subtypes through interchangeable antigen recognition domains, while maintaining the same core signaling architecture. The BiTE molecules are designed with universal binding patterns to CD3 and SSTR, allowing a single platform to address multiple neuroendocrine tumor types. This universality reduces manufacturing complexity by standardizing production processes across different target specificities
Data Source
AI summary
Disclosed are compositions and methods for targeted treatment of SSTR-expressing cancers. For example, disclosed herein are Bispecific T-Cell Engaging (BiTE) molecules (fusion polypeptides) (also referred to herein as bispecific molecules) that are able to crosslink CD3 complex on immune effector cells with SSTR2 on NETs. Also disclosed are chimeric antigen receptor (CAR) polypeptides that can be used with adoptive cell transfer to target and kill SSTR-expressing cancers. Also disclosed are immune effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with a SSTR-expressing cancer, such as a neuroendocrine tumor, that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs.